NEW YORK, NY / ACCESSWIRE / August 9, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of ResMed Inc. ("ResMed") (NYSE:RMD) concerning possible violations of federal securities laws.
On August 3, 2023, ResMed reported results for the fourth quarter of fiscal 2023. Analysts lowered their ratings in response to ResMed's report, citing concerns over market share and gross margins. Following ResMed's announcements, on August 4, 2023, ResMed's stock price fell from $219.95 per share to $179.25 per share, a decline of more than $40 per share. To obtain additional information, go to:
https://zlk.com/pslra-1/resmed-inc-lawsuit-submission-form?prid=94733&wire=1
or contact Joseph E. Levi, Esq. either via email at [email protected] or by telephone at (212)363-7500.
WHY LEVI & KORSINSKY: Over the past 20 years, Levi & Korsinsky LLP has established itself as a nationally-recognized securities litigation firm that has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. The firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services' Top 50 Report as one of the top securities litigation firms in the United States. Attorney Advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
[email protected]
Tel: (212)363-7500
Fax: (212)363-7171
https://zlk.com/
SOURCE: Levi & Korsinsky, LLP